EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study

Stephen A Harrison, Juan P Frias, K Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J Tillman, Ali Moulton, Brittany de Temple, Arian Zari und 4 weitere

Clinical Gastroenterology and Hepatology · 2025-01 · 23 (1) · 103-113

DOI: 10.1016/j.cgh.2024.02.022 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025-01. Verfasst von Stephen A Harrison und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Oxford, Oxford, United Kingdom; Pinnacle Clinical Research, San Antonio, Texas. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: In phase 2 studies, efruxifermin, an Fc-FGF21 analog, significantly reduced steatohepatitis and fibrosis in patients with non-alcoholic steatohepatitis, now called metabolic dysfunction-associated steatohepatitis (MASH), for which there is no approved treatment. Type 2 diabetes (T2D) and obesity are prevalent among patients with MASH and increasingly treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs). This study evaluated the safety and efficacy of efruxifermin in patients with MASH, fibrosis, and T2D taking a GLP-1RA. METHODS: Cohort D was a double-blind, placebo-controlled, phase 2b study in adults with T2D and MASH with fibrosis (F1-F3) on stable GLP-1RA therapy randomized (2:1) to receive efruxifermin 50 mg or placebo, once weekly for 12 weeks. The primary endpoint was safety and tolerability of efruxifermin added to a stable dose of GLP-1RA. Secondary endpoints included changes in hepatic fat fraction (HFF), markers of liver injury and fibrosis, and metabolic parameters. RESULTS: Adults (N = 31) with T2D and MASH fibrosis (F1-F3) on a stable GLP-1RA (semaglutide, 48.4%; dulaglutide, 45.2%; liraglutide, 6.5%) received efruxifermin 50 mg (n = 21) or placebo (n = 10) for 12 weeks. The addition of efruxifermin to a GLP-1RA appeared safe and well-tolerated. The most frequent efruxifermin-related adverse events were mild to moderate gastrointestinal events. One patient receiving efruxifermin discontinued due to nausea, and another withdrew consent. There were no treatment-related serious adverse events. After 12 weeks, efruxifermin reduced HFF by 65% (P < .0001 vs placebo) compared with a 10% reduction for placebo (GLP-1RA alone). Efruxifermin also improved noninvasive markers of liver injury, fibrosis, glucose, and lipid metabolism while maintaining GLP-1RA-mediated weight loss. CONCLUSIONS: The tolerability profile of efruxifermin added to GLP-1RA appeared comparable to that of either drug alone, while also significantly reducing HFF and noninvasive markers of fibrosis in patients with MASH and T2D. Liver health in patients already on a GLP-1RA may be further improved by addition of efruxifermin. CLINICALTRIALS: gov, Number: NCT05039450.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleFemaleMiddle AgedDouble-Blind MethodAdultTreatment OutcomeAgedPlacebosDrug Therapy, CombinationImmunoglobulin Fc FragmentsFibroblast Growth FactorsHypoglycemic AgentsDrug-Related Side Effects and Adverse Reactions

Stichwörter der Autor:innen

Fibroblast Growth Factor 21GLP-1 AnalogHispanic/LatinxNAFLD

Substanzen

PlacebosImmunoglobulin Fc FragmentsFibroblast Growth FactorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • University of Oxford, Oxford, United Kingdom; Pinnacle Clinical Research, San Antonio, Texas.
  • Velocity Clinical Research, Los Angeles, California.
  • Lucas Research, Morehead, North Carolina.
  • Tandem Clinical Research, Marrero, Louisiana.
  • Covenant Metabolic Specialists, LLC, Sarasota, Florida; Covenant Research and Clinics LLC, Ft. Myers, Florida.
  • Tampa Bay Medical Research, Clearwater, Florida.

Zitieren

APA

Harrison, S. A., Frias, J. P., Lucas, K. J., Reiss, G., Neff, G., Bollepalli, S., Su, Y., Chan, D., Tillman, E. J., Moulton, A., de Temple, B., Zari, A., Shringarpure, R., Rolph, T., Cheng, A., & Yale, K. (2025). Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clinical Gastroenterology and Hepatology, 23(1), 103-113. https://doi.org/10.1016/j.cgh.2024.02.022

Vancouver

Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S, et al. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clinical Gastroenterology and Hepatology. 2025;23(1):103-113. doi:10.1016/j.cgh.2024.02.022

BibTeX
@article{Harrison2025,
  author = {Harrison, Stephen A and Frias, Juan P and Lucas, K Jean and Reiss, Gary and Neff, Guy and Bollepalli, Sureka and Su, Yan and Chan, Doreen and Tillman, Erik J and Moulton, Ali and de Temple, Brittany and Zari, Arian and Shringarpure, Reshma and Rolph, Timothy and Cheng, Andrew and Yale, Kitty},
  title = {Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  volume = {23},
  number = {1},
  pages = {103--113},
  doi = {10.1016/j.cgh.2024.02.022}
}
Kostenlos starten →